Equities analysts expect Boston Scientific Co. (NYSE:BSX) to post $0.44 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Boston Scientific’s earnings, with the lowest EPS estimate coming in at $0.43 and the highest estimate coming in at $0.45. Boston Scientific reported earnings per share of $0.39 during the same quarter last year, which suggests a positive year-over-year growth rate of 12.8%. The company is scheduled to report its next quarterly earnings report on Wednesday, February 5th.
According to Zacks, analysts expect that Boston Scientific will report full year earnings of $1.56 per share for the current year, with EPS estimates ranging from $1.55 to $1.58. For the next year, analysts anticipate that the company will post earnings of $1.79 per share, with EPS estimates ranging from $1.73 to $1.86. Zacks’ EPS calculations are an average based on a survey of research firms that cover Boston Scientific.
Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.39 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.01. Boston Scientific had a net margin of 10.49% and a return on equity of 23.47%. The business had revenue of $2.71 billion during the quarter, compared to the consensus estimate of $2.68 billion. During the same quarter in the prior year, the firm earned $0.35 EPS. The company’s revenue for the quarter was up 13.1% compared to the same quarter last year.
In other news, SVP Maulik Nanavaty sold 34,035 shares of the stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $42.65, for a total value of $1,451,592.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Arthur C. Butcher sold 6,329 shares of the stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $41.98, for a total transaction of $265,691.42. The disclosure for this sale can be found here. Insiders sold 86,449 shares of company stock valued at $3,576,948 over the last quarter. Insiders own 0.66% of the company’s stock.
Several institutional investors have recently bought and sold shares of BSX. Alps Advisors Inc. lifted its stake in Boston Scientific by 12.2% during the second quarter. Alps Advisors Inc. now owns 17,230 shares of the medical equipment provider’s stock valued at $741,000 after purchasing an additional 1,874 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Boston Scientific by 2.2% during the second quarter. Charles Schwab Investment Management Inc. now owns 5,654,915 shares of the medical equipment provider’s stock valued at $243,049,000 after purchasing an additional 119,294 shares during the last quarter. North Star Investment Management Corp. acquired a new stake in Boston Scientific during the third quarter valued at approximately $89,000. Cullen Frost Bankers Inc. lifted its stake in Boston Scientific by 28.7% during the second quarter. Cullen Frost Bankers Inc. now owns 407,826 shares of the medical equipment provider’s stock valued at $17,528,000 after purchasing an additional 90,900 shares during the last quarter. Finally, MidWestOne Financial Group Inc. acquired a new stake in Boston Scientific during the second quarter valued at approximately $444,000. Institutional investors and hedge funds own 91.60% of the company’s stock.
Shares of NYSE:BSX traded down $0.19 during trading on Friday, reaching $41.51. 7,139,066 shares of the company’s stock traded hands, compared to its average volume of 9,872,340. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.31 and a quick ratio of 1.04. Boston Scientific has a 12 month low of $31.56 and a 12 month high of $43.84. The company has a 50 day moving average of $40.51 and a 200-day moving average of $40.46. The stock has a market capitalization of $58.09 billion, a P/E ratio of 28.24, a price-to-earnings-growth ratio of 2.34 and a beta of 0.76.
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
See Also: How Buying a Call Option Works
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.